LUNG-MAP: RILOTUMUMAB AND ERLOTINIB HYDROCHLORIDE OR ERLOTINIB HYDROCHLORIDE ALONE AS SECOND-LINE THERAPY IN TREATING PATIENTS WITH RECURRENT STAGE IV SQUAMOUS CELL LUNG CANCER AND POSITIVE BIOMARKER MATCHES: